INM-755
Epidermolysis Bullosa (wound care)
Key Facts
About InMed Pharmaceuticals
InMed Pharmaceuticals is executing a dual-pillar strategy to de-risk its business model: developing proprietary cannabinoid-based drug candidates for diseases with high unmet need and manufacturing rare cannabinoids for commercial and research use. Its core differentiator is the IntegraSyn™ biosynthesis platform, which enables scalable, consistent production of cannabinoids difficult to source from plants. Key achievements include advancing its lead candidate, INM-755, into clinical trials for epidermolysis bullosa and establishing its capabilities as a potential supplier in the rare cannabinoid market. The company's mission is to apply rigorous pharmaceutical development to cannabinoids, transforming them into defined, reproducible medicines.
View full company profile